Fresenius SE Income After Taxes 2016-2024 | FSNUY
Fresenius SE annual/quarterly income after taxes history and growth rate from 2016 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
- Fresenius SE income after taxes for the quarter ending June 30, 2024 was $-0.013B, a 107.14% decline year-over-year.
- Fresenius SE income after taxes for the twelve months ending June 30, 2024 was $-0.120B, a 107.31% decline year-over-year.
- Fresenius SE annual income after taxes for 2023 was $0.258B, a 88.45% decline from 2022.
- Fresenius SE annual income after taxes for 2022 was $2.23B, a 33.12% decline from 2021.
- Fresenius SE annual income after taxes for 2021 was $3.335B, a 3.42% increase from 2020.
Fresenius SE Annual Income After Taxes
(Millions of US $) |
| 2023 |
$258 |
| 2022 |
$2,230 |
| 2021 |
$3,335 |
| 2020 |
$3,225 |
| 2019 |
$3,392 |
| 2018 |
$4,386 |
| 2017 |
$3,428 |
| 2016 |
$2,981 |
| 2015 |
$2,551 |
Fresenius SE Quarterly Income After Taxes
(Millions of US $) |
| 2024-06-30 |
$-13 |
| 2024-03-31 |
$314 |
| 2023-12-31 |
$-589 |
| 2023-09-30 |
$169 |
| 2023-06-30 |
$181 |
| 2023-03-31 |
$497 |
| 2022-12-31 |
$403 |
| 2022-09-30 |
$555 |
| 2022-06-30 |
$600 |
| 2022-03-31 |
$672 |
| 2021-12-31 |
$870 |
| 2021-09-30 |
$803 |
| 2021-06-30 |
$853 |
| 2021-03-31 |
$809 |
| 2020-12-31 |
$739 |
| 2020-09-30 |
$874 |
| 2020-06-30 |
$806 |
| 2020-03-31 |
$805 |
| 2019-12-31 |
$926 |
| 2019-09-30 |
$840 |
| 2019-06-30 |
$816 |
| 2019-03-31 |
$811 |
| 2018-12-31 |
$1,027 |
| 2018-09-30 |
$813 |
| 2018-06-30 |
$1,689 |
| 2018-03-31 |
$858 |
| 2017-12-31 |
$1,030 |
| 2017-09-30 |
$809 |
| 2017-06-30 |
$790 |
| 2017-03-31 |
$800 |
| 2016-12-31 |
$851 |
| 2016-09-30 |
$758 |
| 2016-06-30 |
$734 |
| 2016-03-31 |
$638 |
| 2015-12-31 |
$7,951 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$19.458B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
